Hydroxybenzoic Acid Antioxidants Mitochondrial Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mitochondria-targeted antioxidants, such as MitoQ and SKQ1, have shown limited efficacy and safety concerns in therapeutic applications for neurodegenerative diseases and other oxidative stress-related conditions, highlighting the need for more effective and safe mitochondrial modulators.
Innovation Solution
Development of novel mitochondriotropic antioxidants based on hydroxybenzoic acids and analogues (AntiOxBENs) with robust antioxidant and iron-chelating properties, designed to accumulate within mitochondria while maintaining a low cytotoxicity profile, which are synthesized using specific chemical strategies to enhance bioavailability and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MitoQ and SKQ1 are used as mitochondria-targeted antioxidants, then mitochondrial oxidative damage is reduced, but efficacy and safety concerns limit their therapeutic application
Solution Approach 1:
The patent modifies the chemical structure of known mitochondria-targeted antioxidants by changing the quinone moiety to hydroxybenzoic acid derivatives, thereby altering pharmacological parameters to improve safety while maintaining mitochondrial targeting capability through the TPP cation
Solution Approach 2:
The invention creates composite molecular structures combining the lipophilic cation TPP with hydroxybenzoic acid derivatives, forming a new class of compounds that integrate mitochondrial targeting functionality with enhanced antioxidant and iron-chelating properties
2Reliability
If exogenous antioxidants are administered to compensate for insufficient endogenous defence systems, then overall antioxidant response is improved, but the complexity of blocking complex networks of oxidative damage pathways increases
Solution Approach 1:
The hydroxybenzoic acid derivative compounds possess multiple functions: they act as antioxidants, iron chelators, and mitochondrial targets simultaneously, allowing a single agent to address multiple aspects of oxidative damage without requiring complex multi-component systems
3Reliability
If hydroxybenzoic acid derivatives are used as antioxidants, then antioxidant activity is provided, but bioavailability and druggability limitations reduce their usefulness in therapy
Solution Approach 1:
The lipophilic cation TPP acts as an intermediary that facilitates the delivery of hydroxybenzoic acid derivatives across cellular and mitochondrial membranes, thereby improving bioavailability and enabling therapeutic application of compounds that would otherwise have poor membrane permeability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new antioxidants effectively prevent mitochondrial oxidative stress, delay lipid peroxidation, and demonstrate a better safety profile compared to existing compounds, showing potential in treating various diseases associated with mitochondrial dysfunction and oxidative stress.
Implementation Method 1
This type of lipophilic cation can cross the mitochondrial membrane and accumulate within the mitochondrial matrix taking advantage of the inner membrane electric potential gradient
Implementation Method 2
Excessive ROS production, if not counteracted by intrinsic defence mechanisms, can cause oxidative damage on cellular components such as lipids, proteins and nucleic acids
Implementation Method 3
robust antioxidant and iron-chelating properties
Data Source
Figure 1A
Figure 1B
Figure 2~3B
AI summary
The present disclosure relates to the design and synthesis of new mitochondriotropic antioxidant compounds based on hydroxybenzoic acids and analogues. Furthermore, this disclosure is also related to the methods and uses of the hydroxybenzoic based derivatives and analogues, for example, in the field of human and animal diseases, for instance to treat mitochondrial dysfunction or mitochondrial deficiencies, and cosmetics, for instance to prevent or delay skin aging.